House Oversight Committee Chairman Rep. Darrell Issa, California Republican, is concerned that a new Food and Drug Administration rule that would allow generic drug companies to change warning labels without approval has no health benefits, and was designed to placate special interest groups and could increase lawsuits. (Associated Press)
Featured Photo Galleries
